The Sense of Smell (SoS) Atlas: Its Creation and First Application to Investigate COVID-19 Related Anosmia With a Comprehensive Quantitative MRI Protocol
Abstract
BACKGROUND: The loss of smell (anosmia) has been noted in numerous diseases, including COVID-19. Inflammatory and microstructural alterations are possible underlying mechanisms of anosmia in COVID-19. However, no atlas exists to study olfaction and the associated tissue property changes.
PURPOSE: To develop the sense of smell (SoS) atlas, including gray matter regions and white matter tracts of the olfactory circuit, to investigate the underpinnings of COVID-19 related anosmia.
STUDY TYPE: Retrospective.
SUBJECTS: For the SoS atlas, high-resolution tractograms of 10 healthy controls (HC) of the Human Connectome Project (7 females, 22-35 years) were used. The SoS atlas was applied to 8 subjects with persistent anosmia following COVID-19 (COVID-P, 7 females, 52 ± 12 years), 19 subjects that recovered from COVID-19 anosmia (COVID-R, 14 females, 38 ± 13 years), and 17 HC (8 females, 39 ± 12 years).
FIELD STRENGTH/SEQUENCE: 3 T, 3D inversion recovery, 3D fast field echo, and spin-echo echo-planar imaging sequences.
ASSESSMENT: To create the SoS atlas, regions were identified and tracts were extracted via tractography following biological constraints. MRI metrics sensitive to alterations in neuroinflammation, axonal degeneration, myelin and macromolecular density, and iron were analyzed.
STATISTICAL TESTS: Region-based analysis (p-value < 0.05, false discovery rate (FDR) corrected) and voxel-based analysis (p-value < 0.001 uncorrected, FDR-corrected cluster extent = 5 voxels) were…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.